Tolerability of dipeptidyl peptidase-4 inhibitors: A review

Clinical Therapeutics

Volumn 33, Issue 11, 2011, Pages 1609-1629

  Richard, Kathleen R ^a   Shelburne, Jamie S ^b   Kirk, Julienne K ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b CREIGHTON UNIVERSITY SCHOOL OF PHARMACY AND HEALTH PROFESSIONS   (United States)

Author keywords

Alogliptin; Dipeptidyl peptidase 4 (DPP 4) inhibitor; Linagliptin; Saxagliptin; Sitagliptin; Vildagliptin

Indexed keywords

ACARBOSE; ALOGLIPTIN; BIGUANIDE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLICLAZIDE; GLIPIZIDE; HEMOGLOBIN A1C; INSULIN; LINAGLIPTIN; METFORMIN; METFORMIN PLUS VILDAGLIPTIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; VILDAGLIPTIN; VOGLIBOSE;

ABDOMINAL PAIN; ARTHRALGIA; ASTHENIA; BACKACHE; CHOLECYSTITIS; CONSTIPATION; COUGHING; DIARRHEA; DIZZINESS; DYSPEPSIA; FLATULENCE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERHIDROSIS; HYPERTENSION; HYPOGLYCEMIA; INFLUENZA; INSULIN DEPENDENT DIABETES MELLITUS; META ANALYSIS (TOPIC); MONOTHERAPY; MUSCLE SPASM; MUSCULOSKELETAL PAIN; NAUSEA; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OSTEOARTHRITIS; PANCREATITIS; PERIPHERAL EDEMA; PHARYNGITIS; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SINUSITIS; SUBCORNEAL PUSTULAR DERMATOSIS; TREMOR; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING; WEIGHT GAIN;

DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS; PLACEBOS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 82855179439     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.09.028     Document Type: Review

References (84)

1. Nauck M.A., Vilsboll T., Gallwitz B., et al. Incretin-based therapies. Diabetes Care 2009, 32:S223-S231.
2. Drucker D.J. Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes. Expert Opin Investig Drugs 2003, 12:87-100.
3. Richter B., Bandeira-Echtler E., Bergerhoff K., et al. Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes. Vasc Health Risk Manag 2008, 4:753-768.
4. Campbell R.K. Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus. Clin Ther 2011, 33:511-527.
5. Drucker D.J., Nauck M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006, 368:1696-1705.
6. Campbell R.K. Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus. Ann Pharmacother 2007, 41:51-60.
7. Neumiller J.J., Wood L., Campell R.K. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus. Pharmacotherapy 2010, 30:463-484.
8. Drab S.R. Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects. Pharmacotherapy 2010, 30:609-624.
9. Monami M., Cremasco F., Lamanna C. Predictors of response to dipeptidyl peptidase-4 inhibitors: evidence from randomized clinical trials. Diabetes Metab Res Rev 2011, 27:362-372.
10. Esposito K., Cozzolino D., Bellastella G., et al. Dipeptidyl peptidase-4 inhibitors and HbA1c target of < 7% in type 2 diabetes: meta-analysis of randomized controlled trials. Diabetes Obes Metab 2011, 13:594-603.
11. White J. Efficacy and safety of incretin-based therapies: clinical trial data. J Am Pharm Assoc 2009, 49:S30-S40.
12. Deacon C.F. Dipeptidyl peptidase -4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab 2011, 13:7-18.
13. Scheen A.J. Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions. Clin Pharmacokinet 2010, 49:573-588.
14. Scheen A.J. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab 2010, 12:648-658.
15. Borja-Hart N.L., Whalen K.L. Saxagliptin: a new dipeptidyl peptidase 4 inhibitor for type 2 diabetes. Ann Pharmacother 2010, 44:1046-1053.
16. Galvus (vildagliptin) [product information] 2011, Novartis Pharmaceuticals UK Ltd, Surrey, UK.
17. Nowicki M., Rychlik I., Haller H., et al. Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment. Diabetes Obes Metab 2011, 13:523-532.
18. Nathan D.M., Holman R.R., Buse J.B., et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2009, 32:193-203.
19. He Y.L., Sabo R., Picard F., et al. Study of the pharmacokinetic interaction of vildagliptin and metformin in patients with type 2 diabetes. Curr Med Res Opin 2009, 25:1265-1272.
20. He Y.L., Valencia J., Zhang Y., et al. Hormonal and metabolic effects of morning or evening dosing of the dipeptidyl peptidase IV inhibitor vildagliptin in patients with type 2 diabetes. Br J Clin Pharmacol 2010, 70:34-42.
21. Herman G.A., Bergman A., Stevens C., et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 2006, 91:4612-4619.
22. Chan J.C., Scott R., Ferreira J.C., et al. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab 2008, 10:545-555.
23. He Y., Serra D., Wang Y., et al. Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus. Clin Pharmacokinet 2007, 46:577-588.
24. Ligueros-Saylan M., Foley J.E., Schweizer A., et al. An assessment of adverse effects of vildagliptin vs. comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of phase ii and iii clinical trials. Diabetes Obes Metab 2010, 12:495-509.
25. Ristic S., Byiers S., Foley J., et al. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diabetes Obes Metab 2005, 7:692-698.
26. Pratley R.E., Jauffret-Kamel S., Galbreath E., et al. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm Metab Res 2006, 38:423-428.
27. Kikuchi M., Abe N., Kato M., et al. Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2009, 83:233-240.
28. Dejager S., Razac S., Foley J.E., et al. Vildagliptin in drug-naïve patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm Metab Res 2007, 39:218-223.
29. Pi-Sunyer F.X., Schweizer A., Mills D., et al. Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes. Diabetes Res Clin Pract 2007, 76:132-138.
30. Scherbaum W.A., Schweizer A., Mari A., et al. Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes Metab 2008, 10:1114-1124.
31. Scherbaum W.A., Schweizer A., Mari A., et al. Efficacy and tolerability of vildagliptin in drug-naïve patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes Metab 2008, 10:675-682.
32. Iwamoto Y., Kashiwagi A., Yamada N., et al. Efficacy and safety of vildagliptin and voglibose in Japanese patients with type 2 diabetes: a 12-week, randomized, double-blind, active-controlled study. Diabetes Obes Metab 2010, 12:700-708.
33. Pan C., Yang W., Barona J.P., et al. Comparison of vildagliptin and acarbose monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabet Med 2008, 25:435-441.
34. Bosi E., Dotta F., Jia Y., et al. Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naïve patients with type 2 diabetes mellitus. Diabetes Obes Metab 2009, 11:506-515.
35. Schweizer A., Dejager S., Bosi E. Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Obes Metab 2009, 11:804-812.
36. 1c over 1 year in drug-naïve patients with type 2 diabetes. Diabet Med 2007, 24:955-961.
37. Göke B., Hershon K., Kerr D., et al. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin. Horm Metab Res 2008, 40:892-895.
38. Foley J.E., Sreenan S. Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naïve patients with type 2 diabetes. Horm Metab Res 2009, 41:905-909.
39. Rosenstock J., Kim S.W., Baron M.A., et al. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab 2007, 9:175-185.
40. Rosenstock J., Baron M.A., Dejager S., et al. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care 2007, 30:217-223.
41. Rosenstock J., Niggli M., Maldonado-Lutomirsky M. Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-naïve patients with type 2 diabetes mellitus. Diabetes Obes Metab 2009, 11:571-578.
42. Pratley R.E., McCall T., Fleck P.R., et al. Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies. J Am Geriatr Soc 2009, 57:2011-2019.
43. Covington P., Christopher R., Davenport M., et al. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes. Clin Ther 2008, 30:499-512.
44. DeFronzo R.A., Fleck P.R., Wilson C.A., Mekki Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control. Diabetes Care 2008, 31:2315-2317.
45. Rosenstock J., Inzucchi S., Seufert J., et al. Initial combination therapy with alogliptin and a pioglitazone in drug-naïve patients with type 2 diabetes. Diabetes Care 2010, 33:2406-2408.
46. Williams-Herman D., Engel S., Round E., et al. Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,426 patients with type 2 diabetes. BMC Endocr Disord 2010, 10:7.
47. Alba M., Sheng D., Guan Y., et al. Sitagliptin 100 mg daily effect on DPP-4 inhibition and compound-specific glycemic improvement. Curr Med Res Opin 2009, 25:2507-2514.
48. Nonaka K., Tsubouchi H., Okuyama K., et al. Effects of once-daily sitagliptin on 24-h glucose control following 4 weeks of treatment in Japanese patients with type 2 diabetes. Horm Metab Res 2009, 41:232-237.
49. Hanefeld M., Herman G.A., Wu M., et al. Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes. Curr Med Res Opin 2007, 23:1329-1339.
50. Nonaka K., Kakikawa T., Sato A., et al. Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 2008, 79:291-298.
51. Iwamoto Y., Taniguchi T., Nonaka K., et al. Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus. Endocr J 2010, 57:383-394.
52. Raz I., Hanefeld M., Xu L., et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006, 49:2564-2571.
53. Mohan V., Yang W., Son H.Y., et al. Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea. Diabetes Res Clin Pract 2009, 83:106-116.
54. Aschner P., Kipnes M.S., Lunceford J.K., et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006, 29:2632-2637.
55. Barzilai N., Guo H., Mahoney E.M., et al. Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Curr Med Res Opin 2011, 27:1049-1058.
56. Iwamoto Y., Tajima N., Kadowski T., et al. Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial. Diabetes Obes Metab 2010, 12:613-622.
57. Aschner P., Katzeff H.L., Guo H., et al. Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes. Diabetes Obes Metab 2010, 12:252-261.
58. Goldstein B.J., Feinglos M.N., Lunceford J.K., et al. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007, 30:1979-1987.
59. Williams-Herman D., Johnson J., Teng R., et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Curr Med Res Opin 2009, 25:569-583.
60. Williams-Herman D., Johnson J., Teng R., et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes Obes Metab 2010, 12:442-451.
61. Scott R., Wu M., Sanchez M., et al. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract 2007, 61:171-180.
62. Doucet J., Chacra A., Maheux P., et al. Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus. Curr Med Res Opin 2011, 27:863-869.
63. Rosenstock J., Sankoh S., List J.F. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naïve patients with type 2 diabetes. Diabetes Obes Metab 2008, 10:376-386.
64. Henry R., Smith S., Schwartz S., et al. Effects of Saxagliptin on β-cell stimulation and insulin secretion in patients with type 2 diabetes. Diabetes Obes Metab 2011, 13:850-858.
65. Rosenstock J., Aguilar-Salinas C., Klein E., et al. Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes. Curr Med Res Opin 2009, 25:2401-2411.
66. Jadzinsky M., Pfützner A., Paz-Pacheco E., et al. Saxagliptin given in combination with metformin as initial therapy improves glycemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab 2009, 11:611-622.
67. Heise T., Graefe-Mody E.U., Hüttner S., et al. Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients. Diabetes Obes Metab 2009, 11:786-794.
68. Forst T., Uhlig-Laske B., Ring A., et al. The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2011, 13:542-550.
69. Del Prato S., Barnett A.H., Huisman H., et al. Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab 2011, 13:258-267.
70. Monami M., Iacomelli I., Marchionni N., et al. Dipeptydil peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 2010, 20:224-235.
71. Foley J.E., Jordan J. Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience. Vasc Health Risk Manag 2010, 6:541-548.
72. Pi-Sunyer F.X. The impact of weight gain on motivation, compliance and metabolic control in patients with type 2 diabetes mellitus. Postgrad Med 2009, 12:94-107.
73. Willeman M.J., Mantel-Teeuwisse A.K., Straus S.M., et al. Use of dipeptidyl peptidade-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization Vigibase. Diabetes Care 2011, 34:369-374.
74. Engel S.S., Williams-Herman D.E., Golm G.T. Sitagliptin: Review of preclinical and clinical data regarding incidence of pancreatitis. Int J Clin Pract 2010, 64:984-990.
75. Dore D.D., Seeger J.D., Arnold C.K. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 2009, 25:1019-1027.
76. Information for healthcare professionals-acute pancreatitis and sitagliptin (marketed as Janumet and Januvia) US Food and Drug Administration, Accessed June 10, 2011. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm183764.htm.
77. Amori R.E., Lau J., Pittas A.G. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007, 298:194-206.
78. Stulc T., Sedo A. Inhibition of multifunctional dipeptidyl peptidase-IV: is there a risk of oncological and immunological adverse effects?. Diabetes Res Clin Pract 2010, 88:125-131.
79. Schweizer A., Dejager S., Foley J.E., et al. Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large phase III type 2 diabetes population. Diabetes Obes Metab 2010, 12:485-494.
80. Arase Y., Suzuki F., Kobayashi M., et al. Efficacy and safety in sitagliptin therapy for diabetes complicated by chronic liver disease caused by hepatitis C virus. Hepatol Res 2011, 41:524-529.
81. Accessed August 31, 2011. http://www.ClinicalTrials.gov.
82. Nauck M.A., Meininger G., Sheng D., et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007, 9:194-205.
83. Januvia (sitagliptin) [prescribing information] 2011, Merck & Co, Inc, Whitehouse Station, NJ.
84. Onglyza (saxagliptin) [prescribing information] 2011, Bristol-Myers Squibb Co, Princeton, NJ.